Dr. Kesselring received his doctorate in Organic Chemistry from Washington University in St. Louis, MO. He was also instrumental in establishing a research laboratory for Dr. Scott Gilbertson in the Toxicology Department of the University of Texas Medical Branch at Galveston. Then, in 2005, he joined Chemir Analytical Services where he was responsible for driving a variety of research and development programs dealing with method development and validation, extractables and leachables, and impurities and degradants in pharmaceutical and medical device products. Dr. Kesselring also helped lead Chemir’s newly developed division, Cyanta Analytical Services. In 2008, he took on the role of Director of Analytical Operations and was later promoted to Vice President and General Manager. When Cyanta was purchased by Evans Analytical Group, Dr. Kesselring continued his leadership role as Managing Director of the Life Sciences Division.

Dr. Kesselring has become an industry recognized expert in extractable and leachable programs, authoring many presentations, papers, posters, and articles regarding this topic.

As Chief Science Officer of MoCann Testing, Dr. Kesselring is actively overseeing the development and implementation of Missouri rule compliant, cannabis test methods. These methods are critical for the successful clearance of safe and effective cannabis based medicinal treatments here in Missouri.

Dr. Kesselring also has uniquely positioned science-based business insight as a member of the Missouri Cannabis Trade Association advisory board member of the Manufacturing and Testing committee. While testing is the foundation and backbone of Medicinal Cannabis product safety and efficacy, Dr. Kesselring also deeply understands the need to find efficient intersection of patient and industry requirements and will work towards policy and protocols that resourcefully meet the needs of both suppliers and patients.